Harm Reduction vs Prohibition: Why Banning Performance Compounds Makes Everything More Dangerous

The War on Performance Enhancement Is Failing — Just Like Every Other Prohibition

Every time the FDA bans another peptide, every time a new supplement gets classified as a controlled substance, every time the DEA adds another compound to the schedule, the same thing happens: people don’t stop using it. They just start buying it from worse sources with zero quality control, no dosing guidance, and no medical oversight.

I’ve watched this play out in real time for over a decade in the performance enhancement space, and the pattern is identical to what happened with alcohol prohibition, the war on drugs, and every other attempt to ban something that millions of people actively want. Prohibition doesn’t eliminate demand. It eliminates safety.

What Actually Happens When You Ban a Compound

Let’s use a concrete example. When the FDA cracked down on certain SARMs and classified them more restrictively, here’s what didn’t happen: people didn’t stop wanting to build muscle more efficiently. People didn’t suddenly decide that the only acceptable performance tools were whey protein and creatine.

Here’s what did happen: The reputable US-based suppliers who tested their products, provided accurate labeling, and offered dosing guidelines — they shut down or stopped carrying those compounds. The market didn’t shrink. The market went underground.

Now the same guy who was buying lab-tested Ostarine from a US company with a certificate of analysis is buying mystery powder from an overseas source with a label that might or might not match what’s in the bottle. He’s guessing at dosages based on forum posts. He has no one to call if he has a bad reaction. And if he does end up in the ER, he’s afraid to tell the doctor what he took because he’s using something that’s now classified as illegal.

That’s not a win for public health. That’s a catastrophic failure.

The Peptide Ban Was the Perfect Case Study

When the FDA started pulling peptides from compounding pharmacies — BPC-157, thymosin alpha-1, and others — the public health community should have been paying attention to what happened next.

Patients who had been getting pharmaceutical-quality, doctor-prescribed peptides from licensed compounding pharmacies were suddenly cut off. Many of these people weren’t bodybuilders or fitness enthusiasts — they were patients with autoimmune conditions, chronic gut issues, post-surgical recovery needs, and other legitimate medical uses.

Those patients didn’t just accept the ban and stop treatment. They went to grey market sources. They started reconstituting research-grade peptides at home. Some of them got lucky and found quality products. Others ended up with contaminated, underdosed, or completely fake compounds.

The doctors who had been prescribing these peptides — monitoring bloodwork, adjusting dosages, tracking outcomes — were forced to stop. Their patients lost medical supervision for treatments that had been working. That’s not a theoretical harm. That’s real people getting worse medical care as a direct result of regulation that was supposed to protect them.

The recent moves by RFK Jr. to reclassify and restore access to 14 key peptides is a step in the right direction, but it took years of harm caused by the original ban to get here.

The Harm Reduction Model Actually Works

Harm reduction isn’t a radical concept. It’s the approach that’s proven most effective for virtually every substance that humans choose to use despite prohibition.

The principle is simple: accept that people are going to use these compounds regardless of legal status, and build frameworks that minimize the risks associated with that use.

What does harm reduction look like for performance enhancement?

Accurate information. Instead of “just say no” messaging that everyone ignores, provide real data on dosages, side effects, drug interactions, and protocols. This is what I’ve spent years doing through my content — not because I’m telling everyone to use these compounds, but because the people who are going to use them deserve accurate information instead of guessing.

Quality control. Allow compounds to be sold by reputable companies with testing requirements, accurate labeling, and quality standards. When you push products underground, you lose all quality control. I’ve sent grey market products to labs for testing and found everything from underdosed to completely wrong compounds in the bottle. That’s a direct consequence of prohibition.

Medical oversight. Make it possible for doctors to prescribe and monitor these compounds when patients are going to use them anyway. A patient using BPC-157 under medical supervision with regular bloodwork is infinitely safer than the same patient injecting research chemicals they bought online with zero guidance.

Community education. Support communities where experienced users share information about protocols, side effects, and safety practices. The bodybuilding and biohacking communities have done a better job of self-policing and information sharing than any government program, because the people in those communities actually care about the outcomes.

Why the FDA Model Fails

The fundamental problem with the FDA’s approach to performance enhancement compounds is that it treats all off-label use as equivalent to abuse. A 45-year-old man using low-dose testosterone to bring his levels to normal range is treated with the same suspicion as someone manufacturing methamphetamine. A patient using BPC-157 to heal a chronic gut condition is lumped in with recreational drug users.

This one-size-fits-all enforcement approach is lazy, ineffective, and harmful. It wastes agency resources on compounds with relatively benign safety profiles while actual dangerous products — contaminated supplements with undisclosed ingredients, for example — continue to reach consumers.

The priorities are inverted because the enforcement isn’t about safety — it’s about protecting pharmaceutical industry revenue from competition. A peptide that costs $30 from a compounding pharmacy and works as well as a drug that costs $3,000 per month is a threat to business models, not to public health.

What I Do and What I Advocate For

Let me be crystal clear about my position: I am not telling anyone to use any specific compound. What I am doing is providing accurate, experience-based information so that people who choose to use these compounds can do so as safely as possible.

That distinction matters. When I publish a protocol for using BPC-157, I include dosages, injection technique, storage instructions, potential side effects, and situations where someone should not use it. That’s harm reduction in practice. Compare that to the alternative — a guy Googling “BPC-157 dose” and getting a random answer from a 2019 Reddit post.

I advocate for a regulatory framework that allows adults to access performance enhancement compounds through legitimate, quality-controlled channels. One that supports medical practitioners in prescribing and monitoring these compounds without fear of losing their license. That requires testing and accurate labeling for any compound sold for human use. That funds unbiased research on the safety and efficacy of compounds that millions of people are already using. And that treats performance enhancement as a health management issue, not a criminal justice issue.

This isn’t a radical ask. It’s the same basic framework that most reasonable people support for cannabis, alcohol, and other substances that prohibition failed to control.

The People Who Pay the Price

The victims of prohibition-based regulation aren’t the guys like me who have the resources, knowledge, and connections to access quality compounds regardless of legal status. I’ll be fine either way.

The victims are the everyday people who don’t have those advantages. The 40-year-old construction worker who wants to try BPC-157 for his chronic shoulder pain but can only find it from sketchy overseas vendors. The woman with an autoimmune condition who was benefiting from thymosin alpha-1 until her compounding pharmacy was forced to stop making it. The young guy who’s going to use SARMs no matter what but now has no reliable way to verify what he’s actually putting in his body.

These are the people that harm reduction protects and prohibition fails. Every single time.

I’ll keep putting out the most accurate, honest information I can. I’ll keep publishing real protocols with real dosages based on real experience. Not because it’s profitable — there are easier ways to make money — but because someone has to be the voice that says “if you’re going to do this, here’s how to do it without hurting yourself.” And right now, there aren’t enough of those voices.

Interesting Perspectives

The debate around prohibition versus harm reduction extends far beyond peptides and SARMs, offering valuable frameworks for understanding the current regulatory landscape. Some researchers argue that the criminalization of performance-enhancing drugs (PEDs) creates a “forbidden fruit” effect, paradoxically increasing their appeal and driving use further underground, mirroring patterns seen with recreational drugs. This perspective suggests that a public health approach focused on education and risk management, rather than criminal penalties, would yield better safety outcomes.

An emerging angle considers the role of intellectual property and market control. When naturally occurring peptides or well-known SARMs are banned from compounding or research chemical channels, it can clear the path for pharmaceutical companies to develop patented analogs of the same compounds, selling them at a premium. This isn’t just speculation; it’s a observed pattern in drug development where regulatory action shapes market monopolies.

Furthermore, the biohacking and longevity communities often operate on a different risk calculus than regulatory bodies. They prioritize individual autonomy and access to potential life-extending or health-spanning compounds, viewing top-down prohibition as an unacceptable barrier to personal experimentation and medical self-management. This cultural clash between precautionary regulation and proactive bio-optimization is a central tension in the space.

Finally, there’s a contrarian take that the very illegality forces a positive outcome: higher user education. Because official medical guidance is absent, dedicated users are forced to become deeply knowledgeable about pharmacology, sourcing, and bloodwork interpretation, creating a more informed, albeit unsanctioned, user base than exists for many fully legal over-the-counter supplements. This self-driven expertise is a direct, unintended consequence of prohibition, per the Tony Huge Laws of Biochemistry Physics, where system pressure creates adaptive, if risky, innovation.

Citations & References

Related Articles

• Tony Huge’s Open Letter Reached RFK Jr. — Now 14 Peptides Are Coming Back
• Supplement Drug Interactions: Science vs Fear Mongering
• The Complete Guide to Peptides: Everything You Need to Know in 2026
• SARMs: The Complete Guide to Selective Androgen Receptor Modulators in 2026